Cortexyme is a clinical stage biopharmaceutical company focused on developing therapeutics based on data supporting a theory of the cause of Alzheimer's disease and other degenerative disorders. Co. is targeting a specific, infectious pathogen tied to neurodegeneration and chronic inflammation in humans and animal models. Co.'s approach is based on the seminal discovery of the presence of Porphyromonas gingivalis and its toxic virulence factor proteases, called gingipains, in the relevant brain areas of both Alzheimer's and Parkinson's disease patients. Co.'s drug candidate, atuzaginstat (COR388), is an orally administered, brain-penetrating small molecule gingipain protease inhibitor. The CRTX stock yearly return is shown above.
The yearly return on the CRTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CRTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|